

#### **India I Equities**

# **Building Materials Company Update**

Change in Estimates ☑ Target ☑ Reco □

13 August 2020

### **Century Plyboards**

Weak quarter, though outlook optimistic; maintaining a Buy

After almost no sales in April and May in all its major categories, Century's weak Q1 was broadly as expected. Despite the poor Q1 sales, positive EBITDA was encouraging. Its stretched working capital and increase in debt would normalise as sales rise. We expect cost savings on several measures taken to continue in FY22 and reflect in our margin estimates (downside risk, if not). We like Century for its leading positions in its product categories, strong balance-sheet and healthy FCF generation. At ~12x FY22e P/E, it is our preferred pick in the wood-panel segment. We retain our Buy rating, with a target of ₹171 (earlier ₹169), valued at 15x FY22e P/E. Growth/margin recovery across segments and capex in MDF/PB are key monitorables.

Weak Q4, broadly in line though. Standalone revenue/EBITDA plunged 65%/99% y/y while PAT was a negative ₹85m. Also, subsidiaries performances were impacted. While Q1 was weak, the positive EBITDA despite poor sales was encouraging. CFS, being an essential category, was the least hit. Working capital was stretched by inventory build-up and resulted in debt increasing (by ₹550m q/q). We believe these would be normal as sales improve. Decisions regarding capex and the Laos unit will be made soon.

**All divisions declined 62-69% y/y.** On almost nil sales in April and May, sales in all categories plunged 62-69% y/y, excl. CFS (down only 10%). However, good pent-up demand for products was seen on markets opening. While we expect growth to return gradually, capacity constraints in MDF/PB may restrict growth in case of a strong bounce-back in FY22.

**Cost-saving steps to support margins.** Several cost-reduction steps taken (aiming to save ~₹80m a month) would help the company sail through a tough FY21. We expect these savings to continue in FY22 and reflect in our margin expansion estimates (downside risk if they do not persist).

**Valuation.** We like Century for its diversified product range, leading position in key products and disciplined balance sheet. We retain our Buy recommendation. **Risks:** Rising input costs, currency fluctuations.

FY18	FY19	FY20	FY21e	FY22e
20,238	22,804	23,170	18,267	23,611
1,660	1,489	1,252	1,377	2,536
7.5	6.7	5.6	6.2	11.4
18.1	20.2	24.0	21.8	11.8
10.6	11.4	9.8	11.4	6.7
3.5	3.1	2.8	2.5	2.1
19.5	15.3	11.5	11.3	17.4
11.6	11.1	13.1	9.4	14.4
0.7	0.7	0.7	0.1	0.7
0.6	0.4	0.2	-0.1	-0.2
	20,238 1,660 7.5 18.1 10.6 3.5 19.5 11.6 0.7	20,238         22,804           1,660         1,489           7.5         6.7           18.1         20.2           10.6         11.4           3.5         3.1           19.5         15.3           11.6         11.1           0.7         0.7	20,238         22,804         23,170           1,660         1,489         1,252           7.5         6.7         5.6           18.1         20.2         24.0           10.6         11.4         9.8           3.5         3.1         2.8           19.5         15.3         11.5           11.6         11.1         13.1           0.7         0.7         0.7	20,238         22,804         23,170         18,267           1,660         1,489         1,252         1,377           7.5         6.7         5.6         6.2           18.1         20.2         24.0         21.8           10.6         11.4         9.8         11.4           3.5         3.1         2.8         2.5           19.5         15.3         11.5         11.3           11.6         11.1         13.1         9.4           0.7         0.7         0.7         0.1

Rating: **Buy** 

Target Price: ₹171 Share Price: ₹135

Key data	CPBI IN / CNTP.BO
52-week high / low	₹182 / 95
Sensex / Nifty	38321 / 11306
3-m average volume	\$1.1m
Market cap	₹30bn / \$400.4m
Shares outstanding	222m

Shareholding pattern (%)	Jun'20	Mar'20	Dec'19
Promoters	73.1	73.1	72.9
- of which, Pledged	-	-	-
Free float	27.0	27.0	27.2
- Foreign institutions	6.4	6.9	7.2
- Domestic institutions	9.1	8.2	7.3
- Public	11.5	11.8	12.6

Estimates revision (%)	FY21e	FY22e
Sales	(1)	1
EBITDA	(4)	1
PAT	0	1



Source: Bloomberg

Ashish Poddar Research Analyst

Devanshi Kapadia Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

### **Quick Glance – Financials and Valuations (Consol.)**

Fig 1 – Income statement (₹ m)								
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e			
Net revenues	20,238	22,804	23,170	18,267	23,611			
Growth (%)	11.3	12.7	1.6	-21.2	29.3			
Direct costs	9,860	11,509	11,605	8,832	11,201			
SG&A	7,069	8,279	8,258	6,871	8,257			
EBITDA	3,310	3,016	3,307	2,564	4,153			
EBITDA margins (%)	16.4	13.2	14.3	14.0	17.6			
- Depreciation	907	595	763	690	772			
Other income	79	71	128	161	160			
Interest expenses	358	469	389	218	179			
PBT	2,123	2,023	1,772	1,817	3,363			
Effective tax rate (%)	21.8	26.4	29.3	24.2	24.6			
+ Associates / (Minorities)	-	-	-	-	-			
Net income	1,660	1,489	1,252	1,377	2,536			
Adjusted income	1,660	1,489	1,763	1,377	2,536			
WANS	223	223	223	223	223			
FDEPS (₹ / sh)	7.5	6.7	5.6	6.2	11.4			
FDEPS growth (%)	(14.2)	(10.3)	(15.9)	9.9	84.2			
Gross margins (%)	51.3	49.5	49.9	51.7	52.6			

Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
Share capital	223	223	223	223	223
Net worth	8,516	9,749	10,906	12,238	14,552
Debt	5,346	4,816	2,574	2,074	1,674
Minority interest	184	253	-17	3	23
DTL / (Assets)	23	12	5	7	9
Capital employed	14,069	14,830	13,468	14,322	16,257
Net tangible assets	6,475	8,348	7,764	7,374	6,902
Net intangible assets	18	16	22	22	22
Goodwill	-	-	-	-	-
CWIP (tang. & intang.)	1,261	268	160	60	40
Investments (strategic)	-	-	-	-	-
Investments (financial)	61	64	63	2,063	3,563
Current assets (ex cash)	9,228	9,159	8,344	6,820	8,309
Cash	211	262	248	707	491
Current liabilities	3,186	3,288	3,132	2,724	3,070
Working capital	6,042	5,870	5,211	4,096	5,239
Capital deployed	14,069	14,830	13,468	14,322	16,257
Contingent liabilities	825	435	-	-	-


Fig 3 – Cash-flow statement (₹ m)								
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e			
EBIT (excluding other income)	2,467	2,490	1,763	1,894	3,402			
+ Non-cash items	971	664	493	710	792			
Oper. prof. before WC	3,438	3,154	2,255	2,604	4,193			
- Incr. / (decr.) in WC	729	-97	-802	-1,120	1,133			
Others incl. taxes	-407	216	631	413	805			
Operating cash-flow	3,115	3,035	2,427	3,311	2,256			
- Capex (tang. + intang.)	2,610	1,474	76	200	280			
Free cash-flow	505	1,561	2,351	3,111	1,976			
Acquisitions								
- Div.(incl. buyback & taxes)	267	267	267	45	223			
+ Equity raised	-	-	-	-	-			
+ Debt raised	-318	-530	-2,242	-500	-400			
- Fin investments	0	3	-1	2,000	1,500			
- Misc. (CFI + CFF)	382	710	(142)	107	69			
Net cash-flow	-461	51	-15	459	-216			
Source: Company, Anand Rathi Rese	arch							

Fig 4 – Ratio analysis										
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e					
P/E (x)	18.1	20.2	24.0	21.8	11.8					
EV / EBITDA (x)	10.6	11.4	9.8	11.4	6.7					
EV / Sales (x)	1.7	1.5	1.4	1.6	1.2					
P/B (x)	3.5	3.1	2.8	2.5	2.1					
RoE (%)	19.5	15.3	11.5	11.3	17.4					
RoCE (%) - after tax	11.6	11.1	13.1	9.4	14.4					
RoIC	14.9	12.9	13.6	11.5	18.2					
DPS (₹ / sh)	1.0	1.0	1.0	0.2	1.0					
Dividend yield (%)	0.7	0.7	0.7	0.1	0.7					
Dividend payout (%) - incl. DDT	13.4	14.9	17.8	3.2	8.8					
Net debt / equity (x)	0.6	0.4	0.2	-0.1	-0.2					
Receivables (days)	64	47	40	40	40					
Inventory (days)	69	74	63	60	60					
Payables (days)	32	26	24	24	24					
CFO: PAT %	187.6	203.9	137.7	240.5	89.0					
Source: Company, Anand Rathi Resea	Source: Company, Anand Rathi Research									

Fia 5 -	<ul> <li>Price</li> </ul>	movement










## Financial highlights


				9-	9					
Fig 7 – Financials (standalone)										
₹ m)	Q1 FY20	Q2 FY20	Q3 FY20	Q4 FY20	Q1 FY21	% Y/Y	% Q/Q	FY20	FY19	% Y/Y
Income	5,737	5,894	5,954	5,242	2,007	(65)	(62)	22,827	22,638	1
RM costs	2,921	2,958	3,041	2,563	946	(68)	(63)	11,483	11,816	(3)
Employee costs	845	884	846	866	566	(33)	(35)	3,441	3,277	5
Other expenses	1,045	1,124	1,124	1,112	487	(53)	(56)	4,405	4,542	(3)
EBITDA	926	928	943	701	8	(99)	(99)	3,497	3,004	16
Depreciation	169	170	173	163	143	(16)	(12)	676	500	35
Finance costs	90	108	92	83	50	(44)	(39)	372	446	(16)
Other income	11	86	13	1	46	305	3,950	111	61	83
Exceptional items	-	-	(456)		-		-,	(456)	-	
PBT	679	735	234	456	(139)	(120)	(130)	2,104	2,119	(1)
Tax	197	213	43	69	(54)	(127)	(178)	522	531	(2)
PAT	481	521	191	388	(85)	(118)	(122)	1,582	1,588	(0)
EPS (calculated) (₹)	2.2	2.3	0.9	1.7	(0.4)	(118)	(122)	7.1	7.1	(0)
As % of income			0.0	1.7	(0.4)	bps y/y	bps q/q	7.1	7.1	bps y/y
Gross margins	49.1	49.8	48.9	51.1	52.9	380	177	49.7	47.8	189
	14.7	15.0	14.2	16.5	28.2	1,347	1,166	15.1	14.5	60
Employee costs										
Other expenses	18.2	19.1	18.9	21.2	24.3	606	306	19.3	20.1	(76)
EBITDA margins	16.1	15.7	15.8	13.4	0.4	(1,573)	(1,295)	15.3	13.3	205
Depreciation	3.0	2.9	2.9	3.1	7.1	416	401	3.0	2.2	75
Finance costs	1.6	1.8	1.5	1.6	2.5	95	94	1.6	2.0	(34)
Other income	0.2	1.5	0.2	0.0	2.3	210	228	0.5	0.3	22
PBT	11.8	12.5	11.6	8.7	(6.9)	(1,874)	(1,562)	11.2	9.4	186
Effective tax rate	29.1	29.0	18.3	15.0	38.8	968	2,374	24.8	25.1	(24)
PAT margins	8.4	8.8	3.2	7.4	(4.2)	(1,262)	(1,163)	6.9	7.0	(8)
Revenue, by segment (₹ m)						% Y/Y	% Q/Q			% Y/Y
Plywood and allied products	3,157	3,165	3,229	2,792	988	(69)	(65)	12,343	12,781	(3)
Laminate and allied products	1,071	1,352	1,149	1,061	403	(62)	(62)	4,633	4,390	6
Medium-density fibre boards	919	777	966	843	303	(67)	(64)	3,505	2,954	19
Particle boards	249	262	250	231	83	(67)	(64)	991	975	2
CFS services	225	220	220	204	203	(10)	(1)	870	1,037	(16)
Others	125	124	149	120	32	(74)	(73)	518	534	(3)
Revenue mix (%)										
Plywood and allied products	54.9	53.6	54.2	53.2	49.1			54.0	56.4	
Laminate and allied products	18.6	22.9	19.3	20.2	20.0			20.3	19.4	
Medium-density fibre boards	16.0	13.2	16.2	16.1	15.1			15.3	13.0	
Particle boards	4.3	4.4	4.2	4.4	4.1			4.3	4.3	
CFS services	3.9	3.7	3.7	3.9	10.1			3.8	4.6	
Others	2.2	2.1	2.5	2.3	1.6			2.3	2.4	
EBITDA margins (%)										
Plywood and allied products	14.6	15.5	(1.7)	8.1	(7.0)			9.1	13.6	(455)
Laminate and allied products	10.5	14.4	13.9	15.1	5.5	(498)	(953)	13.5	8.8	473
Medium-density fibre boards	23.5	22.3	25.9	25.3	7.5	(1,594)	(1,779)	24.3	13.0	1,135
Particle boards	24.4	29.7	23.9	21.5	10.5	(1,392)	(1,099)	25.0	22.4	254
CFS services	34.2	31.9	34.9	34.1	34.5	29	45	33.8	32.4	134
EBIT (₹ m)	04.2	51.5	34.3	04.1	04.0	23	70	33.0	52.4	104
Plywood and Allied Products	470	450	/EC)	210	(77)			1 00/	1 000	(41)
		178	(56)	219	(77)	(00)	(00)	1,084	1,829	(41)
Laminate and Allied Products	96		141	146		(98)	(99)	561	337	66
Medium Density Fibre Board	169	133	204	164	(25)	(00)	(0.7)	670	200	235
Particle Board	56	66	48	38	1	(98)	(97)	208	177	18
CFS Services	39	32	38	42	42	7	(0)	151	260	(42)
EBIT Margin (%)						bps y/y	bps q/q			bps y/y
Plywood and Allied Products	14.9	14.2	(1.7)	7.9	(7.8)			8.8	14.3	(553)
Laminate and Allied Products	9.0	13.2	12.3	13.8	0.5	(849)	(1,331)	12.1	7.7	443
Medium Density Fibre Board	18.4	17.1	21.1	19.5	(8.2)			19.1	6.8	1,235
Particle Board	22.4	25.4	19.2	16.6	1.4	(2,097)	(1,520)	21.0	18.2	285
CFS Services	17.4	14.5	17.5	20.5	20.7	324	15	17.4	25.1	(766)
Others	6.5	10.1	10.1	(9.9)	(22.8)			4.6	5.1	(56)
Total	14.6	14.8	6.6	11.4	(3.2)	(1,781)	(1,460)	11.8	12.5	(68)
Un-allocable (as % revenue)	(1.2)	(0.5)	(1.1)	(1.1)	(1.2)			(1.0)	(1.2)	20





























### **Valuation**

The building materials sector is faced with several challenges. Yet, we believe in Century's long-term structural growth, supported by macro-economic factors (rising disposable incomes, the government's focus on housing for all, etc.). With its strong brand image (premium-range *Century Club* and the mid-range *Sainik* in plywood) and a diversified product range, it is set to gain from demand revival.

We like Century Ply for its leading positions across its product categories, strong balance-sheet and healthy FCF generation. At ~12x FY22e P/E, we find valuations attractive. Thus, we maintain our Buy rating with a price target of ₹171 (earlier ₹169), valued at 15x FY22e P/E. Growth and margin recovery across segments and the MDF capacity-expansion plan are key monitorables.

Fig 19 – Change ir	Old estimates		New estir	nates	% Var	
(₹ m)	FY20e	FY21e	FY20e	FY21e	FY20e	FY21e
Income	18,426	23,348	18,267	23,611	(1)	1
EBITDA	2,667	4,106	2,564	4,153	(4)	1
PAT	1,374	2,508	1,377	2,536	0	1
Source: Anand Rathi Resea	arch					



#### **Risks**


- Continuing slowdown in real-estate activity. Home renovations/ purchases are the prime drivers for ply-laminate-MDF. Thus, a continuing slowdown may keep the company's growth in the slow lane.
- Unfavourable price movement, availability of key raw materials. Sourcing of key raw materials (face veneers, etc.) at reasonable prices is the key challenge due to environmental concerns. Also, a few of the raw materials such as phenol are linked to crude-oil prices, which are volatile. These pose risks to margins.
- Currency volatility. Since the company imports most of its raw material, currency fluctuations could pare its margins.

#### **Appendix**

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies



#### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views, While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	

#### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2019. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097. Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.